FIBOCOM
13.12.2021 15:32:11 CET | Business Wire | Press release
Fibocom (Stock Code: 300638), a global leading provider of IoT (Internet of Things) wireless solutions and wireless communication modules, announces that its 5G module FG360-NA has been successfully certified by T-Mobile. The module is now qualified to provide wireless connection services under T-Mobile’s nationwide 5G network, helping to further enable 5G applications like FWA (Fixed Wireless Access) in the US market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005397/en/
“We are proud to see our 5G module FG360-NA being certified by T-Mobile. The module is now fully capable to be deployed in the US IoT market. Fibocom will continue to enable industry digital transformation with our advanced 5G technology,” said Gene Santana, VP of Overseas Carriers Certification Dept., Fibocom.
Based on the World's 1st FWA CPE customized 5G SOC chipset, MediaTek T750, Fibocom’s FG360-NA module supports 5G NR Sub-6 band with up to 4.67 Gbps on the downlink and 1.25 Gbps on the uplink theoretically, enabling exciting 5G speed experience. It is worth noting that, integrated with MediaTek T750, the FG360-NA module has high integration and excellent performance that cover global main frequency band & ENDC (with NA and EAU Skus). Supporting 5G standalone network (SA) and non-standalone (NSA) network architectures, the module is also backward compatible with LTE/WCDMA network standards, which helps to reduce investment complexity in the initial stage of 5G construction.
Coming with a built-in quad-core, 2GHz ARM Cortex-A55 CPU, Fibocom’s FG360-NA module supports 5G Sub-6GHz 2CC CA (Carrier Aggregation) up to 200MHz frequency to improve the utilization of spectrum resources and ensure an extended 5G coverage. The FG360-NA module allows end devices to enjoy the full benefits of high-speed 5G + Wi-Fi 6 connectivity, such as Wi-Fi 6 AX1800, AX3600 (Mainstream), AX4200 and AX6000 configurations. The module also supports GNSS, including GPS, GLONASS, Beidou, Galileo and QZSS.
The Fibocom 5G module FG360-NA has a rich extension of interfaces including 2.5Gbps SGMII, USB 3.1/3.0/2.0, PCIe 3.0, GPIO, I2S, UIM and so on. At present, Fibocom’s FG360 module series has been globally certified by FCC/ CE/ PTCRB, and the commercial samples of FG360 are ready for massive production.
For more information, please visit:
- https://www.fibocom.com/en/
- https://www.linkedin.com/company/2807500/admin/
- https://twitter.com/Fibocom_IoT
Resources
- White Paper: 5G to Turbocharge IoT Growth
- White Paper: 5G Network Slicing Empowering Vertical Industries
- Fibocom 5G AIoT Commercialized Products Handbook
- 5G SD-WAN Case Study
- 5G Smart Grid Case Study
About Fibocom
Fibocom is a leading global provider of wireless communication modules and solutions in the sector of IoT (Internet of Things), as well as the first stock-listed (Stock Code:300638) wireless module provider in China. We provide end-to-end IoT wireless communication solutions for telecom operators, IoT equipment manufacturers, and IoT system integrators. With over two decades' engagement in M2M and IoT communication technology and extensive expertise, we are capable of independently developing high-performance wireless communication modules including 5G, LTE/LTE-A, NB-IoT/LTE-M, Android Smart, Automotive, WCDMA/HSPA(+), GSM/GPRS, Wi-Fi, GNSS, etc. Besides reliable, convenient, safe and intelligent IoT communication solutions for almost all vertical industries, we are also geared to customize the best and optimal IoT modules and solutions catering to your special requirements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211213005397/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
